AAS, Suicidality & Dependence
Anabolic-steroid mood effects, dependency syndrome, and body dysmorphia crossover
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (harm documentation)
Reference only. Not medical advice.
What can go wrong
Key risks are withdrawal depression with elevated suicide risk, dependence (compulsive continued use), hypomania/aggression during use, and a self-reinforcing loop with muscle dysmorphia. These harms are easy to overlook because they are not visible on a lab panel, yet they account for some of the most serious outcomes associated with AAS use.
This is something to take to a clinician. The Atlas can tell you what is known about aas, suicidality & dependence in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Supraphysiological anabolic-androgenic steroid (AAS) use is associated with mood disturbances (hypomania, irritability, aggression) during use and, critically, depression during withdrawal as suppressed natural testosterone slowly recovers. Pope, Kanayama, and colleagues have characterized an AAS dependence syndrome in a substantial minority of users, and withdrawal depression is a recognized period of elevated suicide risk. AAS use is closely intertwined with muscle dysmorphia ('bigorexia'), a body-image disorder that both drives use and is reinforced by it. The psychiatric dimension is frequently the most underappreciated harm of the broader androgen-and-enhancement market.
The crash after the cycle can be as dangerous as the cycle itself.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Supraphysiological androgens act on the central nervous system and can produce mood elevation, irritability, and aggression in susceptible users. Because exogenous androgens suppress the hypothalamic-pituitary-gonadal axis, stopping a cycle leaves the body hypogonadal until endogenous production recovers - a low-testosterone state strongly associated with depressed mood, which underlies withdrawal depression and its suicide risk. A dependence syndrome can develop, with continued use to avoid this crash and to maintain body image.
Safety in detail
Anabolic-steroid use and withdrawal are associated with mood disturbance, dependence, and elevated suicide risk during withdrawal. Anyone experiencing withdrawal depression or suicidal thoughts should seek medical and mental-health care.
- Withdrawal depression with elevated suicide risk
- Dependence syndrome in a substantial minority
- Hypomania/aggression during use
- Self-reinforcing loop with muscle dysmorphia
Replacement is not the same as a cycle
These psychiatric harms are associated with supraphysiological/anabolic dosing and abrupt withdrawal, not with monitored physiological replacement. The withdrawal depression in particular reflects the hypothalamic-pituitary-gonadal suppression caused by exogenous androgen excess.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Mood and suicidality assessment
- Withdrawal monitoring after cessation
- Screening for muscle dysmorphia
- Endocrine recovery monitoring
What people get wrong
Often said'Steroids just make you confident, not depressed'
ActuallyThe danger is the crash: withdrawal from suppressed testosterone is associated with clinically significant depression and elevated suicide risk, which is why supervised cessation matters.
Often said'Body image has nothing to do with it'
ActuallyMuscle dysmorphia is both a documented driver of AAS use and reinforced by it; the psychiatric and use behaviors are tightly linked, per Pope and colleagues' research.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Researchers
- Pope, Kanayama, and colleagues (Harvard/McLean)
- During use
- Hypomania, irritability, aggression in a subset
- Withdrawal
- Depression; elevated suicide risk window
- Crossover
- Muscle dysmorphia / body dysmorphia
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about AAS, Suicidality & Dependence. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Pope & Katz1994
Documented mood and psychiatric effects of anabolic-androgenic steroids
Kanayama, Brower, Wood, Hudson, Pope2009-2010
Characterized AAS dependence syndrome and withdrawal-associated depression and suicide risk